Synthesis and Characterization of a Novel Salicin-Cyclodextrin Inclusion Complex

Svera Rusu^*
*Correspondence: Svera Rusu, Department of Pharmaceutical Sciences, Faculty of Pharmacy, “Vasile Goldis Western University of Arad, 86 Liviu Rebreanu, 310045 Arad, Romania, Email:

Introduction

Salicin, a naturally occurring compound found in willow bark, has long been recognized for its anti-inflammatory, analgesic, and antipyretic properties. Due to these benefits, salicin and its derivatives have garnered attention as potential therapeutic agents in various medical applications. However, one of the challenges associated with salicin is its low water solubility, which can limit its bioavailability and therapeutic effectiveness when administered orally. To address these challenges, drug delivery systems such as inclusion complexes have been explored as a means to improve the solubility and stability of hydrophobic compounds like salicin. Among the various methods used to enhance the solubility and bioavailability of poorly soluble drugs, cyclodextrins have emerged as one of the most promising strategies. Cyclodextrins are cyclic oligosaccharides capable of forming inclusion complexes with a variety of guest molecules, such as salicin, due to their unique structure. This article discusses the synthesis and characterization of a salicin–cyclodextrin inclusion complex, highlighting the potential benefits and applications of such a complex in pharmaceutical formulations [1-3].

Description

Cyclodextrins are cyclic oligosaccharides composed of glucose units linked by α-1,4 glycosidic bonds. The most commonly studied types of cyclodextrins are unique structure of cyclodextrins creates a hydrophobic cavity in the center of the molecule, surrounded by a hydrophilic exterior. This structure allows cyclodextrins to encapsulate hydrophobic molecules, forming stable inclusion complexes. The process of forming an inclusion complex occurs when a hydrophobic guest molecule is inserted into the hydrophobic cavity of the cyclodextrin molecule. The guest molecule is held within the cavity by van der Waals forces, hydrogen bonds, and hydrophobic interactions. This interaction improves the solubility, stability, and bioavailability of the guest molecule in aqueous environments. The synthesis of a salicin-cyclodextrin inclusion complex typically involves a process called co-precipitation or solvent evaporation. These methods are designed to encourage the formation of the inclusion complex by promoting the interaction between salicin and cyclodextrin molecules. In this method, a solution of cyclodextrin is mixed with a solution of salicin in a suitable solvent, such as water or ethanol. The solvent is then evaporated, leaving behind the inclusion complex as a solid precipitate. The resulting complex is separated by filtration, washed to remove excess unbound salicin or cyclodextrin, and dried. This method involves dissolving both salicin and cyclodextrin in a common solvent. The solvent is slowly evaporated under reduced pressure, allowing the inclusion complex to form. The complex is then isolated, purified, and characterized. In some cases, additional steps like ultrasonication or mechanical mixing are used to enhance the formation of the inclusion complex. The method chosen depends on factors like the solubility of the compounds, the desired particle size of the complex, and the application intended for the formulation [4,5].

Conclusion

The synthesis and characterization of a salicin-cyclodextrin inclusion complex provide a promising approach to improving the solubility, stability, and bioavailability of salicin. By forming an inclusion complex with cyclodextrin, salicin can be better delivered to its site of action, enhancing its therapeutic efficacy. Characterization techniques such as FTIR, XRD, DSC, SEM, and solubility studies are crucial for understanding the properties of the complex and its potential in pharmaceutical applications. This approach not only opens the door for enhancing the efficacy of salicin but also provides a framework for improving the delivery of other poorly soluble bioactive compounds.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Lee, James I., Vu T. Nguyen, Mei-Ling Chen and Peter C. Adamson. "A rapid, sensitive and selective liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry method for determination of fenretinide (4-HPR) in plasma." J Chromatogr B 862 (2008): 64-71.

Google Scholar, Crossref, Indexed at

2. Orienti, Isabella, Valentina Salvati, Giovanni Sette and Massimo Zucchetti, et al. "A novel oral micellar fenretinide formulation with enhanced bioavailability and antitumour activity against multiple tumours from cancer stem cells." J Exp Clin Cancer Res 38 (2019): 1-17.

Google Scholar, Crossref, Indexed at

3. Gundersen, Thomas E., Nasser E. Bastani and Rune Blomhoff. "Quantitative high‐throughput determination of endogenous retinoids in human plasma using triple‐stage liquid chromatography/tandem mass spectrometry." Rapid Commun Mass Spectromy 21 2007): 1176-1186.

Google Scholar, Crossref, Indexed at

4. Yin, Jing, Kun-Yi Ni, Yue Shen and Peng-Cheng Ma, et al. "Development and validation of a LC–MS/MS method for the determination of viaminate in human plasma." J Chromatogr B 856 (2007): 376-380.

Google Scholar, Crossref, Indexed at

5. Rühl, Ralph. "Method to determine 4‐oxo‐retinoic acids, retinoic acids and retinol in serum and cell extracts by liquid chromatography/diode‐array detection atmospheric pressure chemical ionisation tandem mass spectrometry." Rapid Commun Mass Spectrom 20 (2006): 2497-2504.

Google Scholar, Crossref, Indexed at